Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022

SELL
$6.78 - $12.28 $6,508 - $11,788
-960 Reduced 7.31%
12,170 $139,000
Q1 2022

May 12, 2022

BUY
$7.65 - $15.29 $4,383 - $8,761
573 Added 4.56%
13,130 $120,000
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $164,873 - $307,897
12,557 New
12,557 $187,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $279M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Cibc World Market Inc. Portfolio

Follow Cibc World Market Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc World Market Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cibc World Market Inc. with notifications on news.